White Matter Changes and Cognitive Decline

Diagnosis

White matter hyperintensities (WMHs) significantly increase the risk of cognitive impairment and dementia across diagnostic categories, with the strongest associations seen in mild cognitive impairment (MCI) and post-stroke populations 1, 2
WMHs are highly prevalent in aging populations, with rates as high as 50.9% in ages 40-49 and 96.6% by ages 60-69 2
Executive function is most consistently affected by WMHs, with all studies showing significant associations between baseline WMHs and follow-up performance on executive function tests like Stroop and Trails Making Test 3
Global cognitive function (measured by MMSE) is also frequently affected, with 7/9 studies in cognitively normal individuals showing significant associations 3
MRI is recommended over CT for evaluation of white matter changes due to higher sensitivity for vascular lesions 4
Recommended MRI sequences include: 3D T1 volumetric sequence, fluid-attenuated inversion recovery (FLAIR), T2 (or susceptibility-weighted imaging), and diffusion-weighted imaging 4
Periventricular WMHs (pvWMHs) have stronger associations with incident dementia (HR 1.51) compared to deep WMHs (dWMHs) (HR 1.17) 5
Severe WMHs at baseline produce the largest effect estimate for incident dementia (HR 1.77, 95% CI 1.38-2.10) 1

Control vascular risk factors, as WMHs represent a core feature of cerebral small vessel disease 2
Target executive function deficits, as this domain is most consistently affected by WMHs 3
Regular monitoring with neuropsychological testing focusing on executive function and global cognition is recommended 3

Baseline WMHs increase risk of incident dementia in cognitively normal individuals 1
In MCI populations, WMHs are strongly associated with cognitive decline and conversion to dementia 6
Frontal WMHs are particularly associated with executive function decline 3
WMHs may have less impact on cognitive decline in established AD compared to earlier disease stages 6
Integration with other imaging modalities like amyloid or tau PET may help clarify the relationship between WMHs and cognition 8
Blood-based detection of at-risk individuals could allow for earlier screening and intervention 8